COMMUNIQUÉS West-GlobeNewswire

Microbix Exhibiting at ESCMID Global 2025
09/04/2025
Microbix Showcasing novel QAPs, Customer Presenting Pilot EQA Program Results MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences [...]
Preliminary results for the year ended 31 December 2024
09/04/2025
~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of [...]
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
09/04/2025
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with [...]
American Shared Hospital Services to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub
09/04/2025
Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 SAN FRANCISCO, April 09, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of [...]
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
09/04/2025
WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
09/04/2025
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation Establishes framework for Makana’s kidney, [...]
Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors
09/04/2025
New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board member Significant leadership experience will be instrumental as Augustine [...]
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
09/04/2025
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May [...]
Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025
09/04/2025
ORION CORPORATION PRESS RELEASE 9 APRIL 2025 at 13.30 EEST Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 Orion will publish Interim Report for January–March 2025 on Wednesday [...]
Coave Therapeutics to Attend Upcoming Conferences
09/04/2025
Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following industry conferences: Cell [...]
Emirati Women Chapter Onboards Second Cohort of 62 Participants
09/04/2025
Under the patronage of H.H. Sheikha Fatima bint Mubarak ABU DHABI, United Arab Emirates, April 09, 2025 (GLOBE NEWSWIRE) -- Under the patronage of Her Highness Sheikha Fatima bint Mubarak, Chairwoman of the General [...]
Barbara Weber, M.D., Elected to ITM Supervisory Board
09/04/2025
Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, [...]
ENA Respiratory Partners with University of Maryland and Leading Respiratory Disease Expert to Conduct Phase 2 Study of INNA-051 Antiviral Host Defence Enhancer
09/04/2025
Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infections Study to be led by global health physician scientist, Dr. Justin Ortiz, Professor of [...]
SBC Medical to Present at the Emerging Growth Conference on April 17, 2025
09/04/2025
SBC Medical Group Holdings Incorporated invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. IRVINE, Calif [...]
ValoTx Appoints Marcella Origgi from Johnson & Johnson Innovation as CEO
09/04/2025
HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella [...]
Cytosurge Appoints Magid Haddouchi as Chief Commercial Officer
09/04/2025
New CCO Joins as Cytosurge Engages in Key Scientific Events Across the USA and Beyond ZURICH, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- Cytosurge AG , a leading biotech company in single-cell manipulation and cell [...]
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
09/04/2025
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional poster presentation [...]
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
09/04/2025
OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025 New Clinical Data from Phase 2 Extension Period in Ulcerative Colitis on Long-Term Benefits and Safety of Anti-IL-7R [...]
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025
09/04/2025
OSE Immunotherapeutics présentera des données inédites de la période d’extension de Lusvertikimab à la “Digestive Disease Week” (DDW) 2025 Présentation de nouvelles données cliniques sur les bénéfices et la sécurité à [...]

Pages